Poulton Stuart 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
[F1]2026-03-02$9.41/sh−5,101$47,998→ 94,328 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Signature
/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton|2026-03-03